SIGN-UP NOW! SIGN-UP NOW! Click to become a VoiceAmerica Member for Free!
Voiceamerica radio logo
voiceamerica-health-and-wellness radio logo
Apple logo Google Play Store Kindle store
C. diff. Spores and More
top banner

C. diff. Spores and More

Tuesday at 10 AM Pacific

July 05th 2016:Summit Therapeutics: Ridinilazole, A Microbiome Preserving Antibiotic For The Treatment Of a C. difficile Infection

Join us as we discuss a promising and new treatment for a C. difficile infection. Summit Therapeutic's Ridinilazole, a microbiome preserving antibiotic will be introduced with updates by our two guests Dr. Kevin W. Garey, Chair, Department of Pharmacy Practice and Translational Research, Professor of Pharmacy Practice at the University of Houston College of Pharmacy, Houston, Texas and Dr. Richard Vickers, Chief Scientific Officer at Summit Therapeutics..

Share Email SHARE
Download PDF DOWNLOAD PDF
Get Code GET CODE

Tune in

Tuesday at 10 AM Pacific Time on VoiceAmerica Health and Wellness Channel
LISTEN LIVE
EPISODE ON DEMAND
VIEW HOST PAGE
Questions? Comments?
Call In Live!
Toll Free: 1-866-472-5792
Intl: 001-480-553-5759

Featured Guests

Dr Kevin W Garey, PharmD, MS, FASHP

Chair, Department of Pharmacy Practice and Translational Research Professor of Pharmacy Practice at the University of Houston College of Pharmacy, Houston, Texas Kevin Garey, Pharm.D., M.S., is Chair of the Department of Clinical Sciences and Administration and Professor of Pharmacy Practice at the University of Houston College of Pharmacy in Houston, Texas. He also serves as Division Head, Experiential Therapeutics and Clinical Pharmacology. Additionally, he holds an academic appointment as Adjunct Associate Professor at the University of Texas School of Public Health in Houston. Dr. Garey is an active member of the Society of Infectious Diseases Pharmacists and the American Soci
Read more

Dr. Richard Vickers

Richard Vickers joined Summit Therapeutics company in 2003 and has served as their Chief Scientific Officer, Antimicrobials, since October 2013. During his time at the Summit Therapeutics company, Dr. Vickers has worked in a variety of roles involved in the development and management of various antibacterial therapeutic programs, including our antibiotic program for the treatment of CDI. Prior to joining Summit, Dr. Vickers undertook postdoctoral research studies with Professor Stephen Davies at the University of Oxford and held a Stipendiary Lectureship in organic chemistry at St. Catherine's College in Oxford. ... Dr. Vickers received a Ph.D. in organic chemistry from the Universi
Read more

Share This Episode

facebook Share On Facebook
twitter Share On Twitter
Linkedin Share On LinkedIn
Share Email Share this E-mail
https://www.voiceamerica.com/show/2441/c-diff-spores-and-more 24/10/2017 10:00 24/10/2017 11:00 C. diff. Spores and More https://www.voiceamerica.com/show/2441/c-diff-spores-and-more Join us as we discuss a promising and new treatment for a C. difficile infection. Summit Therapeutic's Ridinilazole, a microbiome preserving antibiotic will be introduced with updates by our two guests Dr. Kevin W. Garey, Chair, Department of Pharmacy Practice and Translational Research, Professor of Pharmacy Practice at the University of Houston College of Pharmacy, Houston, Texas and Dr. Richard Vickers, Chief Scientific Officer at Summit Therapeutics.. VoiceAmerica | Talk Radio | Online Talk Radio studio@voiceamerica.com false DD/MM/YYYY Add to Calendar
Email Host Email the Host

Connect with VoiceAmerica

Download our mobile apps
App store Google play Blackberry store
GPlus Facebook Twitter Linkedin Social Media
Va Press pass